2023 World Conference on Lung Cancer (Posters)-P2.07. Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics

P2.07. Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics - PDF(Abstract)

Back to course

Pdf Summary

This document is an abstract of a presentation titled "Real World Efficacy of First-Line Immunotherapy /- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics" at the WCLC 2023 conference. The presentation discusses the use of immune checkpoint inhibitor (ICI) based regimens as the standard treatment for advanced non-small cell lung cancer (NSCLC) and the need for biomarkers to identify which patients may benefit more from monotherapy or combination therapy. The study evaluated a blood-based proteomic test called Host Immune Classifier (HIC) in 4,779 patients with NSCLC. The results showed that there was no difference in overall survival between patients treated with ICI monotherapy and those treated with ICI combined with chemotherapy. However, stratification of patients based on the HIC test showed that patients with PD-L1 50% and HIC-Cold had better survival when treated with ICI combined with chemotherapy. The study also found that there was no correlation between PD-L1 expression and HIC test classification. The HIC test remained an independent predictor of overall survival in a multivariate analysis. The conclusion suggests that the HIC test may aid in identifying which patients could benefit from the addition of chemotherapy to first-line ICI treatment in metastatic NSCLC. The keywords associated with this presentation are immunotherapy, biomarker, and real-world data.

Asset Subtitle

Wallace Akerley

Meta Tag

Speaker Wallace Akerley

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immunotherapy

chemotherapy

advanced NSCLC

biomarkers

monotherapy

combination therapy

Host Immune Classifier

HIC test

overall survival

metastatic NSCLC